113 related articles for article (PubMed ID: 23104213)
1. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Sinicrope FA; Shi Q
J Natl Cancer Inst; 2012 Nov; 104(21):1616-8. PubMed ID: 23104213
[No Abstract] [Full Text] [Related]
2. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
3. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Bosman FT; Yan P; Tejpar S; Fiocca R; Van Cutsem E; Kennedy RD; Dietrich D; Roth A
Clin Cancer Res; 2009 Sep; 15(17):5528-33. PubMed ID: 19690194
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.
Fearon ER; Carethers JM
Gastroenterology; 2015 Jan; 148(1):10-3. PubMed ID: 25451650
[No Abstract] [Full Text] [Related]
5. [Ways of handling surgical material from patients with colon cancer - standard and additional highly specialized research with colorectal cancer].
Nasierowska-Guttmejer A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S40-50. PubMed ID: 26165033
[No Abstract] [Full Text] [Related]
6. BRAF: a driver of the serrated pathway in colon cancer.
Rustgi AK
Cancer Cell; 2013 Jul; 24(1):1-2. PubMed ID: 23845435
[TBL] [Abstract][Full Text] [Related]
7. [Examination of molecular markers used n the treatment of colon cancer].
Domagała P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
8. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
[TBL] [Abstract][Full Text] [Related]
9. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
10. NO147: the Giving Tree.
Leichman L
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925351
[No Abstract] [Full Text] [Related]
11. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS
J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
15. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
16. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
17. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
19. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
[TBL] [Abstract][Full Text] [Related]
20. Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
Berlin J
N Engl J Med; 2013 Sep; 369(11):1059-60. PubMed ID: 24024844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
